Modulating MUC1 Function on T Cells

Timothy K Erick; Pinku Mukherjee

doi:10.1016/j.it.2019.09.007

Modulating MUC1 Function on T Cells

Trends Immunol. 2019 Nov;40(11):980-983. doi: 10.1016/j.it.2019.09.007. Epub 2019 Oct 22.

Authors

Timothy K Erick¹, Pinku Mukherjee²

Affiliations

¹ Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA; Current address: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. Electronic address: pmukherj@uncc.edu.

PMID: 31653412
DOI: 10.1016/j.it.2019.09.007

Abstract

Immunotherapy is a promising approach to treating cancer. Mucin1 (MUC1), an epithelial glycoprotein, is hypo-glycosylated and overexpressed on epithelial cancers. This renders it a promising target for potential immunotherapeutic approaches. However, MUC1 has also been identified on T cells, which might complicate its potential as a target for immunotherapies.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Animals
Biomarkers, Tumor / metabolism*
Gene Expression Regulation, Neoplastic
Humans
Immunomodulation
Immunotherapy / trends*
Molecular Targeted Therapy
Mucin-1 / immunology
Mucin-1 / metabolism*
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / therapy
T-Lymphocytes / immunology*

Substances

Biomarkers, Tumor
Mucin-1